rivaroxaban

(redirected from Xarelto)
Also found in: Medical.
Translations

rivaroxaban

n rivaroxabán m
References in periodicals archive ?
drug safety agencies probed whether a defective blood-clotting test device affected a trial involving Bayer's anti-blood clotting drug Xarelto.
today announced results from two real world studies the non-interventional XALIA study in patients with deep vein thrombosis (DVT) and a study in patients with cancer-associated thrombosis (CAT) both showing low rates of major bleeding and recurrent venous thromboembolism (VTE) with Xarelto (rivaroxaban).
2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul.
This was the origin of a complaint filed against the makers of the drug Xarelto, an anti-coagulant drug made by Janssen Pharmaceutical.
It's why we consume more pills than any nation on earth and why TV ads are relentlessly selling us Xarelto, Abilify, Stelara, Prodaxa, and dozens of other drugs we never ever guessed we supposedly needed.
In respect to Johnson & Johnson's pharmaceutical division, new drugs such as Xarelto, Simponi, Invokana and Zytiga should continue to lead the growth in pharmaceuticals for the company, according to a Standard & Poor research note.
Xarelto alone is to account for EUR 2 billion of that sum.
Travel Business Review-October 22, 2012--Bayer's Xarelto (Rivaroxaban) Recommended for EU Approval for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE(C)2012] ENPublishing - http://www.
We are delighted to have received a priority review designation for XARELTO for the treatment of PE and DVT, and also to prevent the recurrence of these conditions.
Xarelto, a once daily pill that Johnson & Johnson developed with Bayer AG, was approved last November for atrial fibrillation.
About XARELTO [R] (rivaroxaban) XARELTO[R] belongs to a group of medicines called anticoagulants, and works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots.
Global Banking News-July 25, 2011--Bayer -Phase III J-ROCKET AF Study of Bayer's Xarelto (rivaroxaban) Meets Primary Endpoint(C)2011 ENPublishing - http://www.